文献速递肿瘤 PET/CT放射性药物与辐射防护

强制免疫激活小鼠肿瘤中抗PD-1治疗后对癌细胞[18F]FDG摄取的影响

Influence on [18F]FDG uptake by cancer cells after anti-PD-1 therapy in an enforced-immune activated mouse tumor.
PubMed 文献 · EJNMMI Res · 2020-03-19

本研究在注射cGAMP的B16F10黑色素瘤小鼠模型中,探讨抗PD-1治疗对高免疫激活肿瘤中[18F]FDG摄取的影响。结果显示,第7天时cGAMP/抗PD-1联合组肿瘤的[18F]FDG摄取低于抗PD-1单药组,联合组CD45-癌细胞中GLUT1高表达细胞/己糖激酶II高表达细胞水平显著低于抗PD-1治疗组。作者认为抗PD-1治疗后癌细胞的[18F]FDG摄取可能受肿瘤免疫微环境影响。

要点

  • cGAMP/抗PD-1联合组第7天肿瘤[18F]FDG摄取低于抗PD-1单药组。
  • 联合组CD45-癌细胞中GLUT1高表达/己糖激酶II高表达细胞水平显著低于抗PD-1组。
  • 抗PD-1治疗后癌细胞[18F]FDG摄取可能受免疫细胞浸润、组成和激活状态影响。

核心结论

  • 抗PD-1治疗后癌细胞的[18F]FDG摄取可能受肿瘤免疫微环境影响,包括免疫细胞浸润、组成和激活状态。

研究设计与样本

  • 本研究使用注射环二核苷酸cGAMP的B16F10黑色素瘤小鼠模型,以研究抗PD-1治疗对高免疫激活肿瘤中[18F]FDG摄取的影响。
  • 实验按此前手稿所述方法进行,在治疗前和治疗开始后第7天测量[18F]FDG-PET。

主要发现

  • 第7天时,cGAMP/抗PD-1联合组肿瘤的[18F]FDG摄取低于抗PD-1治疗组肿瘤,PET和离体验证均显示该结果。
  • 抗PD-1和/或cGAMP治疗增加了免疫细胞向肿瘤的浸润水平。
  • cGAMP/抗PD-1联合组CD45-癌细胞中GLUT1高表达细胞/己糖激酶II高表达细胞水平显著低于抗PD-1治疗组肿瘤。
  • 作者认为若肿瘤免疫反应高于某一水平,癌细胞葡萄糖摄取会依该水平降低。
  • 葡萄糖摄取的这种变化可能由抗PD-1治疗组与cGAMP/抗PD-1联合组之间免疫细胞浸润或激活水平的差异所致。

局限性

  • 原文指出B16F10黑色素瘤模型免疫原性弱,因此抗PD-1治疗对高免疫原性癌症模型葡萄糖代谢的影响尚不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-programmed cell death 1 (PD-1) antibody is an immune checkpoint inhibitor, and anti-PD-1 therapy improves the anti-tumor functions of T cells and affects tumor microenvironment. We previously reported that anti-PD-1 treatment affected tumor glycolysis by using 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET). That study showed that anti-PD-1 therapy in a mouse B16F10 melanoma model increased glucose metabolism in cancer cells at the point where anti-PD-1 therapy did not cause a significant inhibition of tumor growth. However, the B16F10 melanoma model is poorly immunogenic, so it is not clear how anti-PD-1 treatment affects glucose metabolism in highly immunogenic cancer models. In this study, we used a cyclic dinucleotide GMP-AMP (cGAMP)-injected B16F10 melanoma model to investigate the effect of anti-PD-1 therapy on [18F]FDG uptake in a highly immune activated tumor in mice. RESULTS: To compare the cGAMP-injected B16F10 model with the B16F10 model, experiments were performed as described in our previous manuscript. [18F]FDG-PET was measured before treatment and 7 days after the start of treatment. In this study, [18F]FDG uptake in tumors in the cGAMP/anti-PD-1 combination group was lower than that in the anti-PD-1 treatment group tumors on day 7, as shown by PET and ex vivo validation. Flow-cytometry was performed to assess immune cell populations and glucose metabolism. Anti-PD-1 and/or cGAMP treatment increased the infiltration level of immune cells into tumors. The cGAMP/anti-PD-1 combination group had significantly lower levels of GLUT1high cells/hexokinase IIhigh cells in CD45- cancer cells compared with tumors in the anti-PD-1 treated group. These results suggested that if immune responses in tumors are higher than a certain level, glucose uptake in cancer cells is reduced depending on that level. Such a change of glucose uptake might be caused by the difference in infiltration or activation level of immune cells between the anti-PD-1 treated group and the cGAMP/anti-PD-1 combination group. CONCLUSIONS: [18F]FDG uptake in cancer cells after anti-PD-1 treatment might be affected by the tumor immune microenvironment including immune cell infiltration, composition, and activation status.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Tomita M, Suzuki M, Kono Y, et al. Influence on [18F]FDG uptake by cancer cells after anti-PD-1 therapy in an enforced-immune activated mouse tumor. EJNMMI Res. 2020. PMID: 32189078. doi:10.1186/s13550-020-0608-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。